Lenz Therapeutics targets 2027 operating expenses of $70-$75 million, excluding stock-based compensation
LENZ•Lenz Therapeutics targets 2027 operating expenses of $70 million to $75 million, about 50% below prior estimates, excluding stock-based compensation; third-quarter 2026 revenue was $2.6 million and cash exceeded $197 million at Sept. 30.
1. Spending and revenue targets
Lenz Therapeutics targets 2027 operating expenses of $70 million to $75 million, about 50% below prior estimates, excluding stock-based compensation. Sales and marketing is expected to account for about 70% of spending, with approximately 40 full-time employees. Third-quarter 2026 revenue reached $2.6 million, up more than 50% sequentially, and cash exceeded $197 million as of Sept. 30, 2026.
